Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 9/20 | 0.62 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.61 |
| ▸ | CCKBR | P32239 | 1/20 | 0.61 |
| ▸ | MC3R | P41968 | 1/20 | 0.61 |
| ▸ | GHSR | Q92847 | 1/20 | 0.61 |
| ▸ | CASP6 | P55212 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | CASP4 | P49662 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | CASP9 | P55211 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13352296 | 0.83 | LMNA (0.47) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| Tetrazepam SCHEMBL29500955 | 0.82 | LMNA (0.65) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| Tetrazepam SCHEMBL157998 | 0.82 | LMNA (0.65) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| Tetrazepam SCHEMBL6832326 | 0.81 | LMNA (0.63) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| Clazolam SCHEMBL23014581 | 0.80 | LMNA (0.47) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5163739 | 0.79 | GABRA1 (0.61) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| Nimetazepam SCHEMBL29374297 | 0.79 | LMNA (1.00) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| Nimetazepam SCHEMBL79886 | 0.79 | LMNA (1.00) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| Nimetazepam SCHEMBL10689471 | 0.77 | LMNA (0.95) | LMNAGABRA1GABRG2GABRB3GABRA5 | |
| Nimetazepam SCHEMBL9542099 | 0.77 | LMNA (0.95) | LMNAGABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2026-01-20 | — | — | US | disclosed |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | BAHCESEHIR UNIVERSITESI (TR) | 2025-11-25 | — | — | US | disclosed |
| US-20250281535-A1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-09-11 | — | — | US | disclosed |
| EP-4401842-B1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-08-27 | — | — | EP | disclosed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | LMNA 1461/4885GABRA1 3124/4885GABRG2 2580/4885 |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | LMNA 757/4885GABRA1 879/4885GABRG2 1092/4885 |
| US-12528794-B2 | MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases | MAOB, MAOA, ME3 | LMNA 1504/4885GABRA1 2361/4885GABRG2 3369/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | LMNA 1524/4885GABRA1 175/4885GABRG2 148/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | LMNA 1243/4885GABRA1 1184/4885GABRG2 1329/4885 |
| US-12478613-B2 | Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases | MAOB, MAOA, HTR2B | LMNA 2895/4885GABRA1 1458/4885GABRG2 1439/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | LMNA 1552/4885GABRA1 3027/4885GABRG2 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.